Alphanate SD/HT ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 288 | Autoimmune acquired coagulation factor deficiency | 1 |
288. Autoimmune acquired coagulation factor deficiency
Clinical trials : 205 / Drugs : 238 - (DrugBank : 31) / Drug target genes : 18 - Drug target pathways : 26
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00555555 (ClinicalTrials.gov) | September 2007 | 7/11/2007 | Efficacy of Alphanate FVIII/VWF Concentrate in Type 3 Von Willebrand Patients | A Post-marketing Observation Study to Assess the Efficacy and Safety of the FVIII/VWF Complex (Human,) Alphanate(R), in Preventing Excessive Bleeding During Surgery in Subjects With Congenital Type 3 Von Willebrand Disease | Von Willebrand Disease | Biological: Alphanate SD/HT | Grifols Biologicals, LLC | NULL | Active, not recruiting | 7 Years | N/A | All | 15 | Phase 4 | United States |